Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2015-09-27 Capital/Financing Update
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Phosphagenics Begins Animal Health & Nutrition Program 2 pages 83.8KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Phosphagenics Limited regarding the initiation of an animal health and nutrition trial using their proprietary TPM technology. It discusses the start of a feed efficiency trial in pigs, expected results, and future plans. There are no financial statements, regulatory certifications, voting results, or management changes reported. The content is an update on a business development milestone rather than a financial report or regulatory filing. The document length is 6278 characters, which is sufficient for a detailed announcement but does not contain financial data or detailed investor presentation material. Therefore, it fits best as a Capital/Financing Update (CAP) since it provides an update on a significant business development that could impact the company's commercial prospects and capital value.
2015-09-27 English
June 2015 Half-year Appendix 4D and Financial report 26 pages 1.9MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half Year Report Period ending on 30 June 2015' and contains detailed financial statements such as Consolidated Income Statement, Balance Sheet, Statement of Cash Flows, Directors' Report, and Independent Auditor's Report. It covers a half-year period ending 30 June 2015, which is a period shorter than a full fiscal year. The content includes comprehensive financial data, management discussion, and operational review for the half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2015
2015-08-30 English
Reconciliation of Non-quoted Securities and Appendix 3B 15 pages 312.1KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Phosphagenics Limited regarding movements in non-quoted securities, including conditional rights and options. It references shareholder approvals at the 2015 Annual General Meeting and details the issue of securities pursuant to those approvals. The document includes an Appendix 3B notice, which is a standard form used on the Australian Securities Exchange (ASX) for new issue announcements and applications for quotation of additional securities. The content focuses on the issuance and reconciliation of securities rather than a full financial report or detailed financial statements. It is not a full annual or interim report, nor is it a management discussion or earnings release. The document is lengthy (15,000 characters) and contains detailed regulatory disclosure about securities issuance, which aligns with a Capital/Financing Update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-08-05 English
Appendix 3Y Change in Directors Interest Dr R Murdoch 2 pages 99.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a change in a director's relevant interests in securities, specifically the acquisition of 15,000,000 conditional rights by Dr. Ross Murdoch. The document includes sections on the nature of the change, dates, and securities held before and after the change. This type of filing is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement but a formal notice of director's interest change.
2015-08-05 English
Appendix 3Z - Final Directors Interest Notice - Mr H Rosen 3 pages 140.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Final Director’s Interest Notice – Mr H Rosen' and includes an Appendix 3Z form, which is a standard ASX form used to notify changes in directors' interests in securities. It references the director stepping down and provides details of securities held or interests related to the director. There is no financial data, earnings information, or report content. The document is a formal announcement of a director's dealing or interest notice, specifically related to director shareholdings and interests. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive notice of director's interest changes.
2015-07-09 English
Phosphagenics July 2015 Newsletter 6 pages 1.2MB
Management Reports Classification · 95% confidence The document is a quarterly newsletter from July 2015 providing updates on company structure, board changes, business units, operations, and finance. It mentions the re-engineering of the Board of Directors, appointments of new directors and general managers, ongoing clinical trials, commercial arrangements, and upcoming half-year financial results to be released later. The document is not a formal financial report but rather a communication update to shareholders about recent developments and strategic progress. It also states that the half-year financial results will be released towards the end of August 2015, indicating this document is a preparatory update rather than a full interim or annual report. The content focuses on management updates, business progress, and operational highlights without detailed financial statements or comprehensive financial analysis. Therefore, this document fits best as a Management Reports (MDA) type, which includes management's explanation of business trends and outlook, rather than a formal Interim Report (IR) or Annual Report (10-K).
2015-07-08 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.